AUTHOR=Pane Fabrizio , Lefevre Guillaume , Kwon Namhee , Bentley Jane H. , Yancey Steven W. , Steinfeld Jonathan TITLE=Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome JOURNAL=Frontiers in Immunology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.935996 DOI=10.3389/fimmu.2022.935996 ISSN=1664-3224 ABSTRACT=
In patients with hypereosinophilic syndrome (HES), mepolizumab reduces the incidence of HES-related clinical signs and symptoms (flares). However, reports characterizing flare manifestations are limited. The double-blind, parallel-group 200622 trial (NCT02836496) enrolled patients ≥12 years old with HES for ≥6 months, ≥2 flares in the previous year, and screening blood eosinophil count ≥1000 cells/μL. Patients maintained ≥4 weeks stable HES therapy, before randomization (1:1) to 4-weekly subcutaneous mepolizumab (300 mg) or placebo, plus baseline HES therapy, for 32 weeks. This